Antiretroviral Therapy 2016-2017: The Continuing Need for Individualized Therapy to Optimize Outcomes Among Diverse HIV Patients
Source: Antiretroviral Therapy 2016-2017: The Continuing Need for Individualized Therapy to Optimize Outcomes Among Diverse HIV Patients

Slideset

Antiretroviral Therapy 2016-2017: The Continuing Need for Individualized Therapy to Optimize Outcomes Among Diverse HIV Patients

In this downloadable slideset, Danielle Ciuffetelli, PharmD, and Elly Fatehi, PharmD, BCPS, review important considerations when selecting initial ART and explore how formularies can be better managed to ensure delivery of optimal care for diverse populations of HIV-infected patients. Illustrative cases provide useful examples of key factors involved in treatment selection, including comorbidities, patient preferences and disposition, concomitant medications, and childbearing potential.
Format: Microsoft PowerPoint (.ppt)
File size: 2.46 MB
Date posted: 1/10/2017
  • Selecting First-line Antiretroviral Therapy in Older Patients: New Data, New Options, Key Considerations

    Giovanni Guaraldi MD - 12/16/2015    2 comments / Last Comment: 2/10/2016
    The management of ART in patients aging with HIV requires clinicians to maintain a detailed knowledge of physical and psychological patient health in order to tailor the most appropriate ART regimen.
  • ART in Older Patients: How I Manage Drug–Drug Interactions With Concomitant Medications

    Anton L. Pozniak MD, FRCP - 10/20/2015    16 comments / Last Comment: 5/10/2016
    As our patients age, they experience metabolic changes and more frequently develop conditions such as bone mineral density loss, cardiovascular disease, diabetes, and malignancies, all of which will affect the choice of first-line ART.
  • Why ART Trials Specific to Women Are Important

    Kathleen E. Squires MD - 9/28/2016    2 comments / Last Comment: 10/19/2016
    Although almost one half of new HIV infections worldwide occur in women, to date, clinical trials for FDA-approved ART regimens have largely been conducted in men. Here is my take on why women-specific ART trials are important.
  • How I Approach Patients Who Are Reluctant to Initiate ART

    Daniel R. Kuritzkes MD - 9/8/2015    5 comments / Last Comment: 9/24/2016
    In this patient case example, I review how I counsel patients who are hesitant to begin first-line ART.
  • My Approach to First-line ART for Patients With High Cardiovascular Disease Risk

    William G. Powderly MD - 10/6/2015    4 comments / Last Comment: 11/8/2015
    When treating HIV in patients with risk factors for CVD, selecting the optimal ART regimen is only part of the equation.